Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $21.77, but opened at $21.13. Genmab A/S shares last traded at $21.27, with a volume of 278,200 shares.

Analysts Set New Price Targets

Several research firms have weighed in on GMAB. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Stock Performance

The company has a market capitalization of $14.23 billion, a P/E ratio of 12.76, a P/E/G ratio of 2.65 and a beta of 0.96. The firm's fifty day moving average is $20.06 and its 200 day moving average is $20.66.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. On average, analysts forecast that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently added to or reduced their stakes in GMAB. EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Headlands Technologies LLC boosted its holdings in shares of Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its position in shares of Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after buying an additional 1,070 shares during the last quarter. Lindbrook Capital LLC raised its stake in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.